HENNIG ARZNEIMITTEL GmbH & Co KG
Pharmaceutical Companies · Main-Taunus-Kreis
HENNIG ARZNEIMITTEL GmbH & Co KG is a pharmaceutical company based in Main-Taunus-Kreis, Hesse, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
HENNIG ARZNEIMITTEL GmbH & Co KG Address & Contact
HENNIG ARZNEIMITTEL GmbH & Co KG at a Glance
HENNIG ARZNEIMITTEL GmbH & Co KG from Main-Taunus-Kreis is a long-established German pharmaceutical company located in Hesse, specializing in the development and marketing of generics and OTC medications. The company was founded in 1946 and has since established itself as a reliable partner in the healthcare sector. HENNIG is known for its products in the areas of cardiovascular, colds, and vitamins, as well as for innovative health solutions that cater to the needs of patients. With a strong vision, the company focuses on research and development to continually improve the quality and efficacy of its pharmaceuticals.
Services and Products
HENNIG offers a comprehensive portfolio of generics and OTC products, including magnesium preparations, calcium supplements, vitamin combinations, and over-the-counter cold remedies. Special attention is paid to products for the treatment of cardiovascular diseases, as these represent common ailments in the population. Additionally, HENNIG continuously works on expanding its range to meet the growing demands in healthcare.
The company produces in its own GMP-certified facilities. This certification guarantees that HENNIG's products are manufactured according to the highest standards in the pharmaceutical industry. The use of state-of-the-art technologies in production, coupled with strict controls throughout the manufacturing process, ensures that all products are not only safe but also highly effective. Furthermore, HENNIG maintains a close collaboration with pharmacists and healthcare providers to maximize the availability of products and provide information about their application.
- Generics: Preparations for the treatment of various diseases that provide the same therapeutic benefit as original products.
- OTC Products: Over-the-counter medications that are easily available through pharmacies.
- Supplementary Ingredients: Vitamins, minerals, and dietary supplements to support overall health.
All products are approved under German drug law and meet the quality standards of the European Pharmacopoeia. This ensures high quality and reliability for consumers and professionals. The sales figures of HENNIG's products show a steady increase, reflecting acceptance and demand in the population.
Location Main-Taunus-Kreis / Hesse
Main-Taunus-Kreis is located west of Frankfurt am Main in the Rhine-Main region and is one of the economically strongest districts in Hesse. The excellent location near Frankfurt and Frankfurt Airport, as well as the good infrastructure, provide HENNIG with optimal conditions for production and distribution in the German and European pharmaceutical market. The location also allows for easy access to important transport links, contributing to the efficiency of logistics processes.
However, it is not only the logistical advantages that make Main-Taunus-Kreis attractive for HENNIG. The area is also rich in professionals in the pharmaceutical field. Numerous universities and research institutions in the region promote the training and continuing education of professionals, which is of great importance to HENNIG. Through collaborations with universities and institutes, HENNIG can access the latest research results and implement innovations more quickly.
Furthermore, HENNIG plays an important role in the regional economy by creating jobs and actively engaging in local initiatives. The company is committed to sustainability and responsible action, which is well received in the region. HENNIG regularly promotes health education initiatives and participates in projects aimed at improving the quality of life in the region.
Other pharmaceutical companies: Overview of Pharmaceutical Companies | Pharmaceutical Companies in Hesse | Pharmaceutical Wholesale
Frequently asked questions about HENNIG ARZNEIMITTEL GmbH & Co KG
What does HENNIG ARZNEIMITTEL GmbH & Co KG do?
HENNIG ARZNEIMITTEL GmbH & Co KG is a pharmaceutical company based in Main-Taunus-Kreis that develops, manufactures or distributes pharmaceutical products. The company is active in the German healthcare market.
Where is HENNIG ARZNEIMITTEL GmbH & Co KG located?
HENNIG ARZNEIMITTEL GmbH & Co KG is headquartered in Main-Taunus-Kreis, Germany. More information can be found on the company's website.
What products does HENNIG ARZNEIMITTEL GmbH & Co KG distribute?
HENNIG ARZNEIMITTEL GmbH & Co KG is active in the pharmaceutical sector. Detailed information on the products offered and therapeutic areas can be found on the company's website or via the contact details provided.
HENNIG ARZNEIMITTEL GmbH & Co KG on social media
More Pharmaceutical Companies in Main-Taunus-Kreis
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.